1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
636A669B09D730EDA85256EB500701C6B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/managing-the-pharmaceutical-in-licensing-process?opendocument
18
19opendocument
2018.97.14.80
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Sales and Marketing » Strategic Alliances » Managing Deal-Making Process » Deal Elements

Managing The Pharmaceutical In-Licensing Process

DB Image

ID: 4674


Features:

Metrics, Graphics, Detailed Process Map


Pages/Slides: 41


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

Research indicates that support staff and organized processes are often insufficient to manage the array of activities required to effectively step through the in-licensing process. Having the appropriate staff and proper procedures to manage in-licensing is necessary to take full advantage of in-licensing opportunities.
Pharmaceutical companies can use this information to evaluate in-licensing processes and organizational structures, perform a gap analysis, and then implement more effective in-licensing management techniques. Based on research of 14 leading pharmaceutical companies, this 41-slide presentation details how organizations conduct in-licensing opportunities, as well as structure and staff in-licensing groups.


Key Topics

  • Integrating Critical Capabilities
    *One company has consolidated all critical in-licensing management capabilities under the Corporate and Business Development group, which reports directly to the CEO.
  • Developing Specializations
    *In-licensing activities at one pharmaceutical company are led by two separate yet well-coordinated organizations based on compound stages.
  • Managing In-licensing Process *One leading pharmaceutical company maps out every stage and step of the licensing process.

Key Findings
  • Dedicated staff conduct scientific, technical and commercial assessments, leading to improved decision quality and speed.
  • Alliance management capabilities are built to ensure continued health of in-licensing partnerships.


Methodology
This information was collected from the Best Practices, LLC Business Excellence Board. It was conducted on behalf of a leading pharmaceutical company based on surveys, interviews and case studies of over 14 benchmark partners from the pharmaceutical and biotechnology industry.

Industries Profiled:
Pharmaceutical; Biotech; Chemical; Health Care; Medical Device


Companies Profiled:
AstraZeneca; Sanofi-aventis; Fujisawa; Boehringer-Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis; Pfizer; Roche

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.